

DEFINITIONS

In this document, unless the context otherwise requires, the following terms and expressions have the meanings set out below. Other terms are explained in the section headed “Glossary of Technical Terms” in this document.

“A Share(s)”	ordinary shares of our Company with a nominal value of RMB1.00 each, listed on the SSE STAR Market and traded in Renminbi
“Accountants’ Report”	the accountants’ report of our Company prepared by Deloitte Touche Tohmatsu and set out in Appendix I to this document
“affiliate(s)”	with respect to any specified person, any other person that directly or indirectly controls, is controlled by, or is under common control with, such specified person
“AFRC”	the Accounting and Financial Reporting Council of Hong Kong
“Articles of Association” or “Articles”	the articles of association of our Company, as amended and effective on the [REDACTED], a summary of which is set out in “Appendix V — Summary of Articles of Association”
“associate(s)”	has the meaning ascribed to it under the Listing Rules
“Audit Committee”	the audit committee of our Board
“Baili Base”	our manufacturing facility in Wenjiang, Chengdu, Sichuan Province, PRC, operated by Baili Pharmaceutical
“Baili-Bio”	Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. (成都百利多特生物藥業有限責任公司), a PRC limited liability company established on February 21, 2017 and formerly known as Chengdu Baili Duote Antibody Drug Co., Ltd. (成都多特抗體藥物有限責任公司), and our wholly-owned subsidiary
“Baili-Bio Base”	our manufacturing facility in Chengdu, Sichuan Province, PRC, operated by Baili-Bio
“Baili Pharm R&D Center”	our R&D facility located in Chengdu, Sichuan Province, PRC
“Baili Pharmaceutical”	Sichuan Baili Pharmaceutical Co., Ltd. (四川百利藥業有限責任公司), a PRC limited liability company established on August 23, 1996 and our wholly-owned subsidiary
“Biokin Shanghai”	Biokin (Shanghai) Biopharmaceutical Technology Co., Ltd. (百利天恒(上海)生物醫藥科技有限責任公司), a PRC limited liability company established on December 22, 2025 and our wholly-owned subsidiary
“BMS”	Bristol-Myers Squibb Company, a global biopharmaceutical company headquartered in the U.S. and listed on the New York Stock Exchange under the ticker symbol BMJ
“BMS Agreement”	the global strategic license and collaboration agreement entered into with BMS on December 11, 2023 and effective on February 8, 2024
“Board” or “Board of Directors”	the board of Directors of our Company
“Business Day” or “business day”	a day on which banks in Hong Kong are generally open for business, other than a Saturday, Sunday or public holiday in Hong Kong
“BVI”	the British Virgin Islands

[REDACTED]

“CDE”	the Center for Drug Evaluation of the NMPA (國家藥品監督管理局藥品審評中心)
-------	--

DEFINITIONS

“Chengdu Jinghe”	Chengdu Jinghe Pharmaceutical Co., Ltd. (成都精核藥業有限責任公司), a PRC limited liability company established on April 2, 2026 and our wholly-owned subsidiary
“Chengdu Yuyanqi”	Chengdu Yuyanqi Biotechnology Co., Ltd. (成都玉顏芪生物科技有限責任公司), a PRC limited liability company established on December 15, 2025 and our wholly-owned subsidiary
“Chief Scientific Officer”	the chief scientific officer of the Company
“China” or “PRC”	the People’s Republic of China, which, for the purposes of this document and geographical references only, excludes Hong Kong, the Macau Special Administrative Region of the PRC, and Taiwan Region
“CIC”	China Insights Industry Consultancy Limited, an independent industry consultant of our Company
“CIC Report”	the industry report commissioned by our Company and independently prepared by CIC, a summary of which is set out in “Industry Overview”
“close associate(s)”	has the meaning ascribed to it under the Listing Rules
“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended from time to time
“Companies (Winding Up and Miscellaneous Provisions) Ordinance”	the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), as amended from time to time
“Company,” “our Company” or “the Company”	Sichuan Biokin Pharmaceutical Co., Ltd. (四川百利天恒藥業股份有限公司), a PRC joint stock company with limited liability incorporated on November 29, 2011 and listed on the SSE STAR Market under stock code 688506 on January 6, 2023, or, where the context requires, its predecessor, Sichuan Tianheng Pharmaceutical Co., Ltd. (四川天恒藥業有限責任公司), or Tianheng Pharmaceutical, a PRC limited liability company established on August 17, 2006
“Compliance Adviser”	TFI Capital Limited
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“connected transaction(s)”	has the meaning ascribed to it under the Listing Rules
“Controlling Shareholder”	has the meaning ascribed to it under the Listing Rules and, unless the context otherwise requires, refers to Dr. Zhu
“core connected person(s)”	has the meaning ascribed to it under the Listing Rules
“Core Product(s)”	has the meaning ascribed to it under Chapter 18A of the Listing Rules and, in the context of our Group, refers to iza-bren and T-Bren
“Corporate Governance Code”	the Corporate Governance Code set out in Appendix C1 to the Listing Rules
“CSDC”	China Securities Depository and Clearing Corporation Limited (中國證券登記結算有限責任公司)
“CSO”	the chief scientific officer of SystImmune
“CSRC”	China Securities Regulatory Commission (中國證券監督管理委員會)
“Director(s)” or “our Director(s)”	the director(s) of our Company
“Dr. Zhu”	Dr. Zhu Yi (朱義), our founder, chairperson of the Board, executive Director, general manager, Chief Scientific Officer and Controlling Shareholder
“EIT”	enterprise income tax
“EIT Law”	the Enterprise Income Tax Law of the PRC (《中華人民共和國企業所得稅法》), as amended from time to time

DEFINITIONS

“Exchange Participant”	a person who may trade on or through the SEHK in accordance with the Listing Rules and is registered as such by the SEHK
“Extreme Conditions”	extreme conditions caused by a super typhoon as announced by the Government of Hong Kong
“FDA”	the Food and Drug Administration of the United States

[REDACTED]

“Group,” “our Group,” “we” or “us”	our Company and its subsidiaries, or any of them as the context requires
“Guide for New Listing Applicants” or the “Guide”	the Guide for New Listing Applicants issued by the SEHK, as amended from time to time
“Guorui Base”	our manufacturing facility in Leshan, Sichuan Province, PRC, operated by Guorui Pharmaceutical
“Guorui Pharmaceutical”	Sichuan Guorui Pharmaceutical Co., Ltd. (四川國瑞藥業有限責任公司), a PRC limited liability company established on December 7, 2005 and our wholly-owned subsidiary
“H Share(s)”	ordinary shares in the share capital of our Company with a nominal value of RMB1.00 each, to be [REDACTED] for and [REDACTED] in Hong Kong dollars and [REDACTED] on the SEHK

[REDACTED]

“Hiatt Technology”	Chengdu Hiatt Technology Co., Ltd. (成都海亞特科技有限責任公司), a PRC limited liability company established on September 29, 2014 and our wholly-owned subsidiary
“Hiatt/Jingxi Base”	our manufacturing facility in Qionglai, Sichuan Province, PRC, operated by Jingxi Pharmaceutical and Hiatt Technology
“HK\$” or “HK dollar” or “Hong Kong dollar”	Hong Kong dollars, the lawful currency of Hong Kong

[REDACTED]

“Hong Kong” or “HK”	the Hong Kong Special Administrative Region of the PRC
---------------------	--

[REDACTED]

DEFINITIONS

[REDACTED]

“IFRS Accounting Standards”	International Financial Reporting Standards, including standards, amendments and interpretations issued by the International Accounting Standards Board and its predecessor bodies
“Independent Third Party(ies)” or “independent third party(ies)”	a person or entity that, to the best of our Directors’ knowledge, information and belief after reasonable enquiries, is not a connected person of our Company under the Listing Rules

[REDACTED]

“Jingxi Pharmaceutical”	Chengdu Jingxi Pharmaceutical Co., Ltd. (成都精西藥業有限責任公司), a PRC limited liability company established on September 29, 2014 and our wholly-owned subsidiary
-------------------------	---

[REDACTED]

“Joint Sponsors”	the joint sponsors named in “Directors and Parties Involved in the [REDACTED]”
“Latest Practicable Date”	July 28, 2026, being the latest practicable date for ascertaining certain information in this document before its publication
“Lhasa Xinbo”	Lhasa Xinbo Pharmaceutical Co., Ltd. (拉薩新博藥業有限責任公司), a PRC limited liability company established on August 22, 2013 and our wholly-owned subsidiary

[REDACTED]

DEFINITIONS

“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended from time to time
“Main Board”	the Main Board of the SEHK
“Ministry of Finance” or “MOF”	the Ministry of Finance of the PRC (中華人民共和國財政部)
“MOFCOM”	the Ministry of Commerce of the PRC (中華人民共和國商務部)
“NDRC”	the National Development and Reform Commission of the PRC (中華人民共和國國家發展和改革委員會)
“NMPA”	the National Medical Products Administration of the PRC (國家藥品監督管理局), successor to the China Food and Drug Administration or CFDA (國家食品藥品監督管理總局)
“Nomination Committee”	the nomination committee of our Board
“Nuoxin Bio”	Chengdu Nuoxin Biotech Co., Ltd. (成都諾芯生物科技有限公司), a PRC limited liability company established on March 4, 2025 and our wholly-owned subsidiary

[REDACTED]

“Panku Capital”	Panku Capital Limited, a company incorporated in the British Virgin Islands on April 16, 2014 and our wholly-owned subsidiary
“PBOC”	the People’s Bank of China (中國人民銀行), the central bank of the PRC
“PRC Company Law”	the Company Law of the PRC (《中華人民共和國公司法》), as amended from time to time
“PRC Legal Advisor”	JunHe LLP, our legal advisor as to PRC laws

[REDACTED]

“Remuneration and Appraisal Committee”	the remuneration and appraisal committee of our Board
“RMB” or “Renminbi”	Renminbi, the lawful currency of the PRC

[REDACTED]

“SAFE”	the State Administration of Foreign Exchange of the PRC (中國國家外匯管理局)
--------	---

DEFINITIONS

“Securities and Futures Ordinance” or “SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended from time to time
“SEHK”	The Stock Exchange of Hong Kong Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited
“SFC”	the Securities and Futures Commission of Hong Kong
“Share(s)”	ordinary shares in the share capital of our Company with a nominal value of RMB1.00 each, comprising A Shares and H Shares
“Shareholder(s)”	holder(s) of the Share(s)
[REDACTED]	
“SSE”	The Shanghai Stock Exchange
“SSE STAR Market”	the Shanghai Stock Exchange Science and Technology Innovation Board (上海證券交易所科創板)
“SSE STAR Market Listing Rules”	the Rules Governing the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange (《上海證券交易所科創板股票上市規則》), as amended from time to time
“STA”	the State Taxation Administration of the PRC (中國國家稅務總局)
[REDACTED]	
“State Council”	the State Council of the PRC (中華人民共和國國務院)
“Strategy and Development Committee”	the strategy and development committee of our Board
“subsidiary(ies)”	has the meaning ascribed to it under the Listing Rules
“substantial Shareholder(s)”	has the meaning ascribed to it under the Listing Rules
“SystImmune”	SystImmune, Inc., a company incorporated in the United States on April 21, 2014 and our wholly-owned subsidiary
“SystImmune Incentive Plan I”	the incentive plan adopted by SystImmune in 2015, the principal terms of which are set out in “Appendix VI — Statutory and General Information — D. SystImmune Incentive Plans”
“SystImmune Incentive Plan II”	the incentive plan adopted by SystImmune in 2022, as amended and restated in 2024, the principal terms of which are set out in “Appendix VI — Statutory and General Information — D. SystImmune Incentive Plans”
“SystImmune Incentive Plan III”	the incentive plan adopted by SystImmune in 2023, the principal terms of which are set out in “Appendix VI — Statutory and General Information — D. SystImmune Incentive Plans”
“SystImmune Incentive Plan IV”	the incentive plan adopted by SystImmune in 2024, the principal terms of which are set out in “Appendix VI — Statutory and General Information — D. SystImmune Incentive Plans”
“SystImmune Incentive Plans”	SystImmune Incentive Plan I, SystImmune Incentive Plan II, SystImmune Incentive Plan III and SystImmune Incentive Plan IV
“SystImmune R&D Center”	our R&D facility located in Seattle, U.S.
“Takeovers Code”	the Codes on Takeovers and Mergers and Share Buy-backs issued by the SFC, as amended from time to time
“Tianze Base”	our manufacturing facility in Lhasa, Tibet Autonomous Region, the PRC, operated by Tianze Pharmaceutical

DEFINITIONS

“Tianze Pharmaceutical”	Lhasa Tianze Pharmaceutical Co., Ltd. (拉薩天澤藥業有限責任公司), a PRC limited liability company established on November 26, 2020 and our wholly-owned subsidiary
“Track Record Period”	the period comprising the financial years ended December 31, 2024 and 2025 and the three months ended March 31, 2026
“Trial Measures for Overseas Listing”	the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Enterprises (《境內企業境外發行證券和上市管理試行辦法》) issued by the CSRC, as amended from time to time

[REDACTED]

“U.S.” or “United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“U.S. dollar”, “US\$” or “USD”	United States dollar, the lawful currency of the United States
“U.S. Securities Act”	the United States Securities Act of 1933, as amended from time to time, and the rules and regulations promulgated thereunder
“VAT”	value-added tax

[REDACTED]

“%”	per cent
-----	----------

Chinese names of laws, regulations, governmental authorities, institutions, natural persons and entities (including certain subsidiaries) are included for ease of reference. If there is any inconsistency, the Chinese names shall prevail.

References to “provinces” of China include provinces, municipalities directly under the central government and provincial-level autonomous regions.

Certain amounts and percentages in this document have been rounded. Totals may therefore differ from the sum of individual amounts.